Eucafluff Expands Businesses in Europe, Asia, and in the United States
11.4.2019 09:00:00 EEST | Business Wire | Press release
Suzano (NYSE:SUZ), a merger between Suzano Papel e Celulose and Fibria, has increased Eucafluff sales in the European, Asian, and US markets. The product is the only eucalyptus-based fluff pulp sold in the world and is used in personal hygiene items such as diapers and sanitary napkins. Eucafluff is considered a reference of innovation and sustainability and, therefore, has been approved by major global manufacturers. In the last 6 months, companies such as Ontex and Vinda International, amongst other local players in Europe, the United States, Japan, and China have been buying from Suzano.
Currently, 86% of Eucafluff's sales are made overseas, in which 25% are sold in Europe. "The acceptance of our fluff pulp in mature markets and multinational companies has confirmed the good performance that eucalyptus fiber can also bring to the hygiene market. We are committed to improving the quality and performance of our client’s end products and this has reflected in the global partnerships we have achieved these past months, " says Alexandre Corrêa, Executive Manager of the Business Unit at Suzano.
Developed by Suzano and resulting from 11 years of research, Eucafluff is the first bleached kraft pulp of eucalyptus fluff type in the world, and is be applied in absorbent products as well as personal hygiene products, disposables like children and adults diapers, sanitary napkins for women, amongst other applications. The key benefits provided by this unique fiber are a higher liquid absorption and retention at product cores and greater comfort and discretion to the end user, such as in the case of application in incontinence pants. These benefits are due to the greater compressibility of the eucalyptus fiber, a feature that has also brought other associated benefits as reduction in packaging size, transportation, and storage costs.
Suzano has 95 years of history and 11 factories, and is present in the lives of more than 2 billion people through its products. The company is the world´s leader in the production of eucalyptus pulp, a raw material developed by the company in the 1960s, is also a world pioneer in the production of eucalyptus fluff and is one of the largest paper manufacturers in Latin America. Since its inception, it has invested in innovative and unique solutions, seeking the substitution of raw materials of fossil origin for other sources of renewable origin.
About Suzano
Suzano , the company resulting from the merger of Suzano Pulp & Paper and Fibria, is committed to being a global reference in the sustainable use of natural resources. The world's leading producer of eucalyptus pulp and one of Latin America’s largest paper producers, Suzano exports to more than 80 countries and, through its products, plays a part in the lives of over two billion people. With ten mills and the joint operation Veracel, Suzano has annual installed capacity of 11 million tons of market pulp and 1.4 million tons of paper. Suzano has approximately 37,000 direct and indirect employees and for over 90 years has invested in innovative solutions based on eucalyptus cultivation that enable it to substitute the use of fossil-based materials with renewable bio-based materials. The company adopts the highest standards of corporate governance on the exchanges where its stock is traded, namely the B3 in Brazil and the NYSE in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190410005839/en/
Contact information
PLANIN – Suzano’s PR Agency
Angélica Consiglio, Beatriz
Imenes and team – www.planin.com
E-mail:
suzano@planin.com - Phone: +55
(11) 2138-8940
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
